Firefly Neuroscience Unveils AI-Powered CLEAR Platform, Boosting EEG Technology with Nvidia Partnership

Firefly Stock Jumps As Nvidia Partnership Boosts AI-Driven EEG Technology For Neurological Care - NVIDIA (NASDAQ:NVDA), Firefly Neuroscience (NASDAQ:AIFF)

Firefly Neuroscience AIFF stock gained after it unveiled its CLEAR (CLeaning EEG ARtifacts) Platform on Tuesday. This next-generation system is designed to deliver electroencephalogram (EEG) data quality. Powered by Nvidia's NVDA L40S GPU with Ada Lovelace architecture, the platform sets a new standard for signal fidelity while accelerating clinical innovation. CLEAR addresses longstanding challenges in EEG recordings, which are frequently disrupted by muscle activity, eye blinks, and environmental interference. Also Read: Amazon, Meta Among Early Adopters Of Nvidia's Jetson Thor Robotics Platform By integrating advanced machine learning and signal processing, the platform produces cleaner, more reliable EEG data, enabling clinicians and researchers to detect subtle neural biomarkers essential for accurate diagnosis, treatment planning, and ongoing monitoring of neurological and psychiatric conditions. Firefly further enhanced the platform with Nvidia GPU acceleration, achieving a 60-80% improvement in processing speeds. The advancement highlights Nvidia's growing footprint in healthcare and life sciences, where it continues to push AI beyond traditional computing environments. Nvidia's stock has gained 34% year-to-date, driven by the AI frenzy as its GPUs gain traction across various end markets, including healthcare and pharma. In parallel, Nvidia CEO Jensen Huang announced two partnerships aimed at reshaping pharmaceutical research. Nvidia expanded its collaboration with Novo Nordisk NVO, using Denmark's Gefion AI supercomputer, BioNeMo, NIM, NeMo microservices, and Omniverse to power drug discovery and physical AI simulations. The partnership will focus on creating single-cell models to predict drug responses and designing drug-like molecules with advanced precision. Nvidia also partnered with IQVIA IQV to launch AI orchestrator agents that manage and accelerate pharmaceutical development workflows. These agents direct specialized sub-agents to rapidly analyze patient records, prescriptions, and lab results, reducing turnaround times from weeks to days. Price Actions: AIFF stock is up 31.27% at $3.41 premarket at the last check on Tuesday. NVDA is up 0.45%. Photo: Shutterstock AIFFFirefly Neuroscience Inc$3.0116.2%Stock Score Locked: Want to See it? Benzinga Rankings give you vital metrics on any stock - anytime. Reveal Full ScoreEdge RankingsMomentum4.96GrowthN/AQualityN/AValue6.65Price TrendShortMediumLongOverviewNVDANVIDIA Corp$180.600.44%IQVIQVIA Holdings Inc$188.01-0.01%NVONovo Nordisk AS$55.21-2.01%Market News and Data brought to you by Benzinga APIs

Firefly Neuroscience Successfully Deploys NVIDIA L40S GPU Acceleration to Power Next-Gen 'CLEAR' Platform

- Unlocks exciting new AI-driven brain biomarker discovery and advancement capabilities - - Substantial processing speed gains while maintaining high signal quality standards - - Comes just months after Firefly announced its acceptance into the NVIDIA Connect Program - and , (GLOBE NEWSWIRE) -- ("Firefly" or the "Company") (NASDAQ: AIFF), an Artificial Intelligence ("AI") company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders, is pleased to unveil its new 'CLEAR' (CLeaning EEG ARtifacts) Platform, a proprietary next-generation preprocessing technology designed to deliver unrivalled electroencephalogram (EEG) data quality. The CLEAR Platform was developed using NVIDIA's L40S GPU with architecture. EEG recordings are notoriously noisy, often contaminated by artifacts such as muscle activity, eye blinks, and environmental interference. The Company's new CLEAR Platform uses state-of-the-art signal processing and machine learning techniques to ensure cleaner, more reliable data - paving the way for novel and scalable clinical insights. In validation testing, the CLEAR Platform demonstrated substantial increases in data quality. By improving the fidelity of EEG signals, researchers and clinicians are now empowered to detect subtle neural biomarkers critical for advancing diagnosis, treatment, and monitoring of neurological and psychiatric conditions. Leveraging NVIDIA GPU acceleration, Firefly has also optimized the CLEAR Platform's performance, achieving 60-80% improvement in processing times. This breakthrough achievement harnesses cutting-edge supercomputing to swiftly preprocess EEG recordings within Firefly's proprietary database -- the world's largest known standardized EEG/ERP repository. "Data quality is the foundation of clinical insight," said Gil Issachar, Firefly's Chief Technology Officer. "By combining our advanced preprocessing methods with NVIDIA GPU acceleration, the CLEAR Platform represents the achievement of a key milestone along our path of building a foundation model of the human brain - unlocking exciting new AI-driven biomarker discovery capabilities and, thereby, accelerating the translation of EEG into actionable tools for patient care." , Chief Executive Officer of Firefly, said, "The launch of our CLEAR Platform will serve as a key part of Firefly's growth strategy, helping us achieve our mission to harness the power of AI and EEG to transform neuroscience and clinical development. With a robust foundation of clean data, the Company is poised to continue to discover and advance breakthrough cognitive brain biomarkers that can support pharmaceutical R&D, clinical trials, and ultimately, patient care." About Firefly Firefly (NASDAQ: AIFF) is an Artificial Intelligence ("AI") company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders. Firefly's FDA-510(k) cleared Brain Network Analytics (BNA™) technology revolutionizes diagnostic and treatment monitoring methods for conditions such as depression, dementia, anxiety disorders, concussions, and ADHD. Over the past 15 years, Firefly has built a comprehensive database of brain wave tests, securing patent protection, and achieving FDA clearance. The Company is now launching BNA™ commercially, targeting pharmaceutical companies engaged in drug research and clinical trials, as well as medical practitioners for clinical use. Brain Network Analytics was developed using artificial intelligence and machine learning on Firefly's extensive proprietary database of standardized, high-definition longitudinal electroencephalograms (EEGs) of over 17,000 patients representing twelve disorders, as well as clinically normal patients. BNA™, in conjunction with an FDA-cleared EEG/ERP system, can provide clinicians with comprehensive insights into brain function. These insights can enhance a clinician's ability to accurately diagnose mental and cognitive disorders and to evaluate what therapy and/or drug is best suited to optimize a patient's outcome. Certain statements in this press release may constitute "forward-looking statements" for purposes of the federal securities laws concerning Firefly. These forward-looking statements include express or implied statements relating to Firefly's management teams' expectations, hopes, beliefs, intentions, or strategies regarding the future. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words "anticipate," "believe," "contemplate," "continue," "could," "estimate," "expect," "intends," "may," "might," "plan," "possible," "potential," "predict," "project," "should," "will," "would" and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements are based on current expectations and beliefs concerning future developments and their potential effects. There can be no assurance that future developments affecting Firefly will be those that have been anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond Firefly's control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to those factors described under the heading "Risk Factors" in the reports and other filings of Firefly with the . Should one or more of these risks or uncertainties materialize, or should any of Firefly's assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. It is not possible to predict or identify all such risks. Forward-looking statements included in this press release only speak as of the date they are made, and Firefly does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.

Firefly Neuroscience Unveils New 'Clear' Platform; Shares Rise Pre-Bell

Firefly Neuroscience, Inc. is an artificial intelligence (AI) technology company dedicated to developing neuroscientific solutions that enhance outcomes for patients with mental illnesses and neurological disorders. The Company has developed its FDA-510(k) cleared Brain Network Analytics (BNA) software platform (the BNA Platform) and is focused on advancing diagnostic and treatment approaches for people suffering from mental illnesses and cognitive disorders, including depression, dementia, anxiety disorders, concussions, and attention-deficit/hyperactivity disorder (ADHD). BNA, utilizing AI and an extensive proprietary electroencephalogram (EEG) database, combines the automatic analysis of Event Related Potentials (ERPs), spectral EEG and behavioral performance data for a comprehensive, and objective data-driven brain health evaluation. The BNA Platform, in conjunction with an FDA-cleared EEG system, can provide clinicians with comprehensive insights into brain function (cognition).